Benign Gynecologic Growth Rate Estimator

Evidence-based growth projections for gynecological conditions

Endometrioma
Ovarian endometriotic cysts, often called "chocolate cysts"
Uterine Fibroid
Benign smooth muscle tumors of the uterus (leiomyomas)
Ovarian Simple Cyst
Fluid-filled sacs with thin walls and no solid components
Ovarian Complex Cyst
Cysts with septations, solid components, or dermoid features
Adenomyosis
Endometrial tissue growing within the uterine muscle wall

Growth Projection Results

Projected Size
Behavior Pattern
Possible Size Range
View Additional Details
Growth Type
Expected Size Change
Monthly Growth Rate
Current Size Projected Size
Clinical Recommendations
Evidence Sources
Disclaimer: This calculator provides estimates based on published research averages. Individual results vary significantly. Always consult with your healthcare provider for personalized medical advice and treatment decisions. This tool is for educational purposes only and does not replace professional medical judgment.
Version 9.0 — View Research Details
NEW IN V9.0: IOTA ADNEX model (AUC 0.92-0.96) for advanced malignancy risk assessment, GnRH antagonist treatments (relugolix/elagolix/linzagolix) with meta-analytic data, updated endometrioma treatment effects from 2024 meta-analysis, pregnancy-specific fibroid growth rates (Mitro 2022 NICHD study), dermoid <10cm malignancy warning, O-RADS v2022 with combined O-RADS+CA-125 scoring (AUC 0.969), adenomyosis MUSA subtype fertility outcomes, and 15+ new verified PubMed references. V8.0: Deterministic calculation mode, ROMA Score Calculator, RMI integration, FIGO/PALM-COEIN fibroid classification, IOTA Simple Rules assessment, prominent 95% confidence interval display, CA-125/HE4 tumor marker integration, enhanced export/print functionality, and comprehensive citation references with PubMed IDs. CORE FEATURES: Li et al. predictive model (82.5% accuracy, AUC 0.825), evidence-based growth patterns (47% decrease, 31% stable, 22% increase for endometriomas), precise treatment-specific rates (continuous OCP: 0.5 cm/year, cyclic OCP: 0.62 cm/year, untreated: 1 cm/year), recurrence risk stratification (odds ratio 3.245 for previous history), concurrent endometriosis assessment (DIE, adenomyosis, bilateral disease), age-specific algorithms (relative risk 0.764 per year), and validated clinical thresholds. Multi-time projections (3-36 months), O-RADS risk stratification, and enhanced laboratory integration (FSH, LH, LDL, total cholesterol). ADENOMYOSIS: Evidence-based progression rates (21.3% overall, 30.77% untreated, 18.34% treated), type-specific algorithms (diffuse vs focal), junctional zone thickness monitoring, and treatment response prediction. FIBROIDS: Comprehensive multiplicity assessment (60-80% have multiple nodules), evidence-based growth projections (9-89% over 18 months, 188% for small fibroids), post-surgical recurrence rates (41.6% at 3 years laparoscopic, 31-43% open), treatment-specific outcomes (UAE: 3.1% recurrence at 1 year, HIFU: 22.5% at 2 years), risk factor stratification.